Novel therapeutic strategy in the treatment of infectious diseases by anti-microbial, endotoxin-neutralizing proteins.
通过抗微生物、内毒素中和蛋白治疗传染病的新治疗策略。
基本信息
- 批准号:10670267
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 2000
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We have found 18kDa cationic anti-microbial proteins (CAP18) with LPS-neutralizing activity from rabbit and human neutrophils. The 27mer C-terminal fragment of human CAP 18 (27mer ; CAP18_<109-135>) has been identified as the anti-microbial and LPS-neutralizing domain. We investigated the effects of modification and/or substitution of amino acid residues of CAP18 peptides on their activities. Acetylation of N-terminal and amidation of C-terminal residues of the 27mer in-creased LPS-neutralizing and antimicrobial activities. Substitution of E_<119> and K_<128> of 27mer to L (27LL) or F (27FF) increased LPS binding activity (〜30-40 fold) and also blocked LPS-induced lethality in mice. Substitution of E_<119> to L_<119> increased LPS-binding activity (〜8 -fold), however, this peptide (27L) could not protect vs. endotoxin shock. Truncation of 9 amino acids from the N-terminus of 27mer (18mer : CAP18_<118-135>) resulted in a significant decrease in LPS-binding activity even though both terminuses are chemically modified. Increasing the hydrophobic amino acid residues (Leucin=L) in 18mer (18LL) increased LPS-binding activity (〜30-fold) and anti-microbial activity versus gram-positive bacteria such as MRSA (methicillin resistant staphylococcus aureus ; >3 -folds), however, 18LL could not protect vs. endotoxin shock in mice. Further replacement of three positions of 18LL by lysine (K) significantly increased LPS-binding activity (〜120-fold), antimicrobial activity vs. gram negative bacteria such as E.coli O157 : H7 and S.typhimurium, and protect mice from endotoxin shock.From these results, the importance of the stability of alpha-helical structure, and the balance of hydrophobic/ hydrophilic (basic) amino acid residues in CAP18 peptide was suggested.
我们从兔和人中性粒细胞中发现了具有lps中和活性的18kDa阳离子抗微生物蛋白(CAP18)。人类CAP18蛋白的c端27mer片段(27mer; CAP18_<109-135>)被鉴定为抗微生物和脂多糖中和结构域。我们研究了修饰和/或取代CAP18肽的氨基酸残基对其活性的影响。27mer的n端乙酰化和c端酰胺化可以增强其lps中和和抗菌活性。将E_<119>和K_<128>的27mer替换为L (27LL)或F (27FF),可提高LPS结合活性(约30-40倍),并阻断LPS诱导的小鼠死亡。将E_<119>替换为L_<119>可提高lps结合活性(约8倍),但该肽(27L)对内毒素休克没有保护作用。从27mer (18mer: CAP18_<118-135>)的n端截断9个氨基酸导致lps结合活性显著降低,尽管这两个末端都经过了化学修饰。增加18mer (18LL)中疏水氨基酸残基(Leucin=L)可提高lps结合活性(约30倍)和对革兰氏阳性细菌如MRSA(耐甲氧西林金黄色葡萄球菌;bbbb3倍)的抑菌活性,但18LL对小鼠内毒素休克无保护作用。赖氨酸(K)进一步取代18LL的三个位置,显著提高了lps结合活性(约120倍),对革兰氏阴性菌(如大肠杆菌O157: H7和鼠伤寒杆菌)的抗菌活性,并保护小鼠免受内毒素休克。这些结果提示了α -螺旋结构的稳定性以及CAP18肽中疏/亲水性(碱性)氨基酸残基的平衡的重要性。
项目成果
期刊论文数量(30)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
平田陸正: "エンドトキシン研究I.-基礎と臨床-"菜根出版. 230 (1998)
Rikumasa Hirata:“内毒素研究 I.-基础和临床”Nane Publishing 230(1998)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
平田 陸正(分担): "エンドトキシン研究シリーズI" 菜根出版, 230 (1998)
平田陆政(撰稿人):《内毒素研究系列 I》Nane Publishing,230(1998)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Swlerzko,AS.: "Biological activities of lipopolysaccharides of proteus spp.and their interactions with polymyxin B and an 18-kDa cationic antimicrobial protein (CAP18)-derived peptide."J.Med.Microbiol.. 49. 127-138 (2000)
Swlerzko, AS.:“变形杆菌属脂多糖的生物活性及其与多粘菌素 B 和 18-kDa 阳离子抗菌蛋白 (CAP18) 衍生肽的相互作用。”J.Med.Microbiol.. 49. 127-138 (2000
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Haishima,Y: "Chemical and biological evaluation of endotoxin contamination on natural latex products."J.Biochem.Mater.Res. (印刷中). (2001)
Haishima,Y:“天然乳胶产品内毒素污染的化学和生物学评估。”J.Biochem.Mater.Res(出版中)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nagaoka I: "Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow." J.Leukoc.Biol.64. 845-852 (1998)
Nagaoka I:“评估骨髓中性粒细胞成熟过程中人类 CAP18 基因的表达。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HIRATA Michimasa其他文献
HIRATA Michimasa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HIRATA Michimasa', 18)}}的其他基金
Endotoxin binding protein : Novel therapeutic strategy of endotoxin shock.
内毒素结合蛋白:内毒素休克的新治疗策略。
- 批准号:
08670314 - 财政年份:1996
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Role of Endotoxin-neutralizing and Antimicrobial Proteins in Innate Immunity
内毒素中和和抗菌蛋白在先天免疫中的作用
- 批准号:
06670300 - 财政年份:1994
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
Role of Endotoxin-binding proteins in Non-specific Protection to Infection
内毒素结合蛋白在非特异性感染保护中的作用
- 批准号:
04670250 - 财政年份:1992
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
Elucidation of the mechanism of endotoxin-induced disseminated intravascular coagulation; Tissue factor activity in macrophage and granulocyte.
阐明内毒素诱导的弥散性血管内凝血的机制;
- 批准号:
61570214 - 财政年份:1986
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Endotoxin binding protein : Novel therapeutic strategy of endotoxin shock.
内毒素结合蛋白:内毒素休克的新治疗策略。
- 批准号:
08670314 - 财政年份:1996
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




